Breaking AI & Tech News Analyzed

High‑resolution satellite imagery released on 25 February 2026 reveals that the Sheikh Mohammed cemetery in Khan Younis has been erased and turned into an Israeli military outpost, while entire neighbourhoods across southern Gaza have been reduced to rubble. The visual evidence, highlighted by Al Jazeera, illustrates a broader pattern of territorial expansion and cultural erasure. Satellite proof of Gaza’s reshaped landscape The updated Google‑Earth layers show the former cemetery, residential blocks in Rafah, the Swedish‑built coastal village, and the Hamad City housing project all replaced by fortified positions, tents and debris. The images capture the disappearance of streets, the flattening of the 752‑unit Tal as‑Sultan housing project, and the conversion of the Rafah border crossing into a heavily fortified military zone. Human‑cost statistics from the ground and from monitors 73,000 Palestinians killed since the conflict escalated. 94 % of Gaza’s cemeteries fully or partially destroyed (Euro‑Med Human Rights Monitor). 97 % of schools damaged or destroyed, leaving 658,000 children without formal education. 1.9 million of 2.3 million residents internally displaced. 60 % of the population has lost their homes completely. Only 5 % of Gaza’s agricultural land remains usable (FAO). Israeli forces now control roughly 70 % of the Strip, up from 60 % earlier this year (leaked video of Benjamin Netanyahu). Implications for the humanitarian and geopolitical landscape The systematic demolition of cemeteries, schools and farms not only erases physical landmarks but also attacks collective memory and food security. With agricultural output slashed to under five percent, experts warn Gaza is on the brink of famine. The loss of educational infrastructure threatens a generation of Palestinians, while the expanding occupation deepens violations of the October cease‑fire and raises the risk of a protracted, “permanent” status quo, as warned by UN envoy Nickolay Mladenov. What lies ahead: risks and possible international responses If the current trajectory continues, Gaza could face a full‑scale famine within months, prompting urgent calls for a new cease‑fire and humanitarian corridors. International pressure may increase as documentation of cultural erasure and mass displacement fuels advocacy campaigns. However, without a clear shift in Israeli policy or renewed diplomatic engagement, the occupation could solidify, making reconstruction and return of displaced families increasingly unlikely.

The LeadA daily pill has shown remarkable results in doubling survival time for patients with pancreatic cancer, the world's deadliest form of the disease. According to clinical trial results presented at the American Society of Clinical Oncology's annual meeting, this breakthrough treatment represents a potential revolution in how we approach a cancer that has seen limited progress for decades.The Breakthrough Drug: DaraxonrasibThe drug in question, daraxonrasib, works by targeting a protein called Kras that fuels nearly all pancreatic cancers. This mechanism represents a significant advancement in treatment strategy, as Kras has been notoriously difficult to target effectively. The drug functions as a Ras(On) multi-selective inhibitor, capable of turning off the Kras protein to stop cancer growth regardless of which variant is present.Impressive Trial ResultsIn the clinical trial involving 500 patients with advanced pancreatic cancer, the results were striking. Those who took daraxonrasib lived an average of 13.2 months, compared to just 6.6 to 6.7 months for patients who received chemotherapy. This represents a near doubling of survival time, with the added benefit of fewer side effects compared to traditional chemotherapy treatments.Industry Impact and Expert ReactionsThe findings have been hailed as a "gamechanger" and "grand slam" by experts in the field. Dr. Rachna Shroff, chief of oncology at the University of Arizona Cancer Center, described the results as "landscape-changing" and "unprecedented survival." When she first read the trial results, conducted by researchers at the Dana-Farber Cancer Institute in Boston, she wept, noting the profound impact this could have on patients after 16 years of treating pancreatic cancer.Dr. Julie Gralow, Asco's chief medical officer, echoed these sentiments, calling the study a "home run" and suggesting it was actually a "grand slam" in terms of its significance.The Ras RevolutionOver 90% of patients with the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (mPDAC), have a mutation in the Kras gene. This discovery has long been considered the "holy grail" in cancer research, particularly for pancreatic cancer where the mutation is nearly ubiquitous and an early driver of cancer growth.Paula Hanford, chief executive of UK-based Pancreatic Cancer Action, called this one of the most significant developments in treatment she had ever seen. Similarly, Anna Jewell, director of services, research and innovation at Pancreatic Cancer UK, described the results as "exciting," noting that the drug gives patients "months more precious time with their loved ones."Future Outlook and ApplicationsThe success of daraxonrasib opens doors for similar treatments targeting Ras genes in other cancers. Experts at the conference noted that because Ras genes fuel various types of cancer, there is hope for breakthroughs in treating lung and colon cancers as well, with similar drugs already in development for these conditions.However, challenges remain in ensuring these promising treatments become widely available to patients. As Jewell pointed out, tragically half of all people with pancreatic cancer die within just three months of diagnosis, making the rapid implementation of such treatments crucial.

Brighton & Hove Albion Women will take the field against Manchester City Women at Wembley on 31 May 2026 for the Women's FA Cup final. City aim to complete a first-ever double, while Brighton chase their inaugural major trophy, playing under the emotional weight of the recent passing of Rado Vidosic, the club’s former head of coaching. Brighton Chasing First Major Trophy Amid Tribute to Late Coach Rado Vidosic The match carries deep personal significance for Brighton. Rado Vidosic, who died from cancer four months earlier, was a pivotal figure in the club’s development. His son, Dario Vidosic, who grew up watching Wembley finals, now leads the team onto the pitch, honoring his father's legacy. Match Timing, Historical Context and Key Figures Kick‑off: 3:00 pm BST (13:00 GMT) City’s ambition: First domestic double in club history. Brighton’s goal: First Women’s FA Cup title since the competition’s inception. Key players: Khadija “Bunny” Shaw (City) – recently secured a four‑year contract extension; Ruth Keenan (Brighton) – leading scorer this season. Historical note: City have won the league this season; Brighton have never lifted the cup. Potential Shift in Women’s Football Power Balance A Brighton victory would signal a breakthrough for clubs outside the traditional powerhouses, potentially encouraging greater investment in smaller teams. Conversely, a City win would cement their dominance and could accelerate the professionalisation of the women's game across England, attracting more sponsors and media attention. What the Result Could Mean for Both Clubs If City wins: Reinforces their status as the premier English women’s side, boosting brand value and likely influencing future player recruitment. If Brighton wins: Provides a morale boost, validates the club’s development pathway, and may spur increased fan engagement and funding. Long‑term outlook: Either outcome will shape the narrative for the 2026‑27 season, affecting league dynamics, TV rights negotiations and grassroots participation.

The Concept of 'Mind Children' A few months ago, an AI researcher from Europe attended a dinner party in Silicon Valley. During one of the many courses, the host addressed his guests, all of whom worked in AI. The researcher paraphrased his message like this: “Isn’t it amazing that we are the last generation of humans who will need to think about procreating biologically? We were lucky enough to be born at a time where we can simply upload our consciousnesses instead.” The Book That Sparked the Conversation The book in question was Hans Moravec’s Mind Children: The Future of Robot and Human Intelligence, which was first published in 1988, and which at the time, according to economist and futurist Robin Hanson of George Mason University, caused a big splash in a small pond – the community of robotics and machine-learning experts to which Moravec belonged. The Data Analysis Moravec’s book is more philosophical treatise than technological manual, but the central idea is that cultural evolution has long since taken over from biological evolution as the most powerful force shaping humanity. The logical extrapolation of this is that the information that encodes our future selves would soon be packed into hardware and software rather than DNA. The Impact Analysis Angela Aristidou, who studies the real-life deployment of AI at University College London, is not surprised that Moravec’s book is enjoying a revival. She says that what in 1988 might have read like science fiction – and still might to most of us – looks eminently realisable to those in the know. The Prediction Hanson shares his conviction that the revolution is inevitable, as soon as AI attains something experts agree to call human-level intelligence. “We are going to generate an explosion of things like us in the future, who will be different from us in many ways,” Hanson says. “To the extent that they have minds somewhat like ours, they are our mind children.”

The Escalating Drone CampaignUkrainian drones have struck energy and industrial targets across several Russian regions, Russian authorities say, in an escalating campaign of strikes against infrastructure. In Saratov, a region on the Volga River with several oil refineries that has come under regular Ukrainian attack in recent years, Governor Roman Busargin said on Sunday on Telegram that "civil infrastructure" had been damaged in the overnight strikes.Strategic Targeting of Energy InfrastructureUkraine's military confirmed that it had struck the Saratov oil refinery overnight, but denied Russian accusations that it had hit the Zaporizhzhia nuclear power plant in Russian-occupied territory. In the Kirov region, northeast of Moscow and about 1,300km (800 miles) from Ukraine, Governor Alexander Sokolov said drones had hit a facility in the Urzhumsky district. The Ukrainian army confirmed the attack, saying it had also hit the Lazarevo oil-pumping station in the region.Regional Impact and Civilian CasualtiesGovernors in the Rostov, Voronezh and Belgorod regions, all of which border Ukraine, also reported strikes, and three civilians were injured in Belgorod. On Ukraine's Russian-controlled Crimean Peninsula, Moscow-backed Governor Sergei Aksyonov said authorities were introducing restrictions on sales of petrol, though he did not specify the reason. Ukraine for months has been attacking fuel infrastructure in southwestern Russia close to Crimea.International Support and Future StrategySeparately on Sunday, President Volodymyr Zelenskyy said Ukraine received a new Iris-T air defence missile launcher from Germany as he asked for the provision of more air defence ammunition from Kyiv's allies. "We also need missiles for air defence systems to have sufficient capabilities to repel Russian attacks," Zelenskyy said on Telegram.

The Lead: Liverpool at a CrossroadsAs Liverpool prepares for life after Arne Slot, the club faces significant challenges that will define their immediate future. The Dutchman's tenure ended without the dominance expected, leaving a squad in need of strategic overhaul both on and off the pitch. The new manager inherits a team that must rediscover its identity while addressing key personnel departures and tactical shortcomings.Style Evolution: From Heavy Metal to Soft RockPerhaps Mohamed Salah's style of communication wasn't the slickest, but he was correct that Liverpool need to redefine the style of football they play. Everything on the pitch last season under Arne Slot felt very placid as Liverpool failed to dominate opponents and were often found overrun. The new head coach will want to demonstrate his plans and implement an attacking style to best use what is available to him. Anfield does not want to witness back-foot football, fans want to see a swagger to those in red. Supporters and Slot suffered from a disconnect in the final months. The Dutchman was hindered by not possessing the vivacious personality of Jürgen Klopp nor the results in the end, and the aforementioned tedious style. The successor will want to put fans at the forefront and build a strong bond between stands and dugout, built on a platform of attractive play.Investment Analysis: Underperforming Key SigningsAfter spending heavily last summer trying to build a squad capable of dominating the Premier League for years to come, it was difficult to pick out someone who thrived. Hugo Ekitiké was the best of the new arrivals but record signings Florian Wirtz and Alexander Isak barely made the season's footnotes. Isak could at least attribute his struggles to fitness and injury problems, including a leg fracture, but the German's first taste of English football was a sour one. He never looked comfortable as a No 10, physically finding it tough going as speed on the ball and strength in battle were lacking. Getting the best out of a clearly talented player must be a priority, because Wirtz has the capabilities to open defences and help Liverpool control games but needs a confidence boost and an arm around the shoulder.Structural Impact: Midfield Deficiencies and Leadership VacuumWirtz is part of a wider midfield issue that lacks physicality and an obvious No 6. Ryan Gravenberch was elected as the man for the role by Slot, which worked well when the possession stats were in Liverpool's favour but finding someone who can break things up effectively is advisable. Every other team have someone who can break up play but Liverpool lack someone in that role. Not since Georginio Wijnaldum or Fabinho have the club possessed someone capable of overwhelming opponents with their physical attributes and in an evolving sport, this oversight must end. Dominik Szoboszlai being moved around the pitch was unhelpful because he can be one of the best central midfielders in the world but needs a defined position to make his own.The players departing Anfield are weighed down with individual and team trinkets, thanks to the success they have enjoyed with Liverpool. Arguably, the influence of Salah and Andy Robertson on the pitch waned in their final season with the club but their experience and winning mentality will be a huge loss to the dressing room and training ground. Ibrahima Konaté is another exiting, providing a recruitment headache the club were not fully anticipating. It does beg the question if it is the right time to allow Alisson Becker, who has suffered from injury problems in recent times, to be sold and allow a new generation to start afresh, with Virgil van Dijk leading the transition. There are plenty of potential internal candidates who can take on greater responsibility but it may require a change in transfer strategy to acquire players in their late-20s with Champions League experience to help give the right balance.Defensive Rebuild: Addressing Key DeparturesKonaté's contract expiration will be softened by Jérémy Jacquet's impending arrival but further investment is required. Van Dijk's longevity is unknown so finding a partnership for the long term will be critical; a more rugged centre-back like Nottingham Forest's Murillo could be an ideal choice to offer balance and greater aggression. Competition for Milos Kerkez will be important, but if Andoni Iraola does take the job the reunion could get the best out of the Hungarian and get him to flourish after a mixed first year on Merseyside. On the opposite side, continuity would help everyone because Slot was forced to trying numerous people in the role, many out of position. Ideally, Conor Bradley or Jeremie Frimpong can make it their own, having struggled to replace Trent Alexander-Arnold, although both have suffered with injury problems. If they can stay fit, they both possess the quality to be a solution, especially if clever coaching can embrace their attacking prowess and incorporate more defensive discipline.Future Outlook: Rebuilding the AttackSlot insisted that new wingers would change the dynamic next season but he will not be the one to benefit. Salah is off, Federico Chiesa cannot carry on as a bit-part, so will almost certainly leave too, freeing up some space on the flanks. Rio Ngumoha offered brief teenage glimpses of excitement as someone with the pace and trickery to get past full-backs. Frimpong, brought in as a right-back, was more often found on the wing because he possessed the speed Slot desired in those areas, while also offering a further indication that the transfer dealings left a lot to be desired. They did not replace the maverick tendencies of Luis Díaz and Cody Gakpo has never looked a natural winger. Targeting new wide men will be imperative. RB Leipzig's Yan Diomande, Brighton's Yankuba Minteh or Athletic Club's Neco Williams would be ideal candidates to bring thrust to a side lacking dynamism and get supporters off their seats.

The Lead: Unprecedented Cancer Treatment SuccessDoctors have hailed "unprecedented" trial results that show a triple-action cancer jab can eradicate entire tumours in patients. In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments.The Breakthrough: Amivantamab's Triple-Action ApproachThe jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether.The smart jab targets cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumours grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack the tumour.The Clinical Trial Data: Impressive Response RatesIn the trial, 102 patients with head and neck cancer, the world's sixth most common cancer, were given the jab. Tumours shrank or disappeared completely in 43 patients, including 28 whose tumours shrank significantly and 15 who saw them eradicated entirely.Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.The Impact Analysis: New Hope for Treatment-Resistant CancersKevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR), said: "These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking."Researchers also highlighted that the trial focused on people with head and neck cancers that did not include those with human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. That is particularly significant, they said, since head and neck cancers not caused by HPV are usually harder to treat, making progress in this group hugely important.The Patient Experience: Transforming Quality of LifeOne of the first patients to benefit was Carl Walsh, 56, who was diagnosed with tongue cancer in May 2024 and joined the OrigAMI-4 trial at the Royal Marsden in July 2025. "I was initially treated with both chemotherapy and immunotherapy, which unfortunately were not successful," he said. "At that point, I was recommended for the OrigAMI-4 trial. I'm now on my 17th cycle of treatment and I'm very pleased with the progress so far."Unlike many cancer treatments, amivantamab is given as a tiny jab under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to deliver in outpatient clinics.The Future Outlook: Expanding Treatment ApplicationsThe results will be presented on Sunday in Chicago at the world's largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco).Amivantamab, developed by Johnson & Johnson, is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.Prof Kristian Helin, the chief executive of the ICR, said: "This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options. Achieving this level of tumour response and encouraging survival outcomes in such a challenging-to-treat group represents a significant step forward."

The Cancellation of Kanye West's Concert in Italy Kanye West's concert in Italy has been cancelled over 'public order and safety issues'. The 48-year-old rapper, who changed his name to Ye in 2021, was due to perform at the Pulse of Gaia festival at the RCF Arena in Reggio Emilia on 18 July. Concerns Over Antisemitic Remarks The city's prefect, Salvatore Angieri, stopped the gigs after 'concerns' from the local Jewish community over previous antisemitic remarks by West. West has been criticized for his antisemitic comments, including a song called 'Heil Hitler in 2025' and advertising a swastika T-shirt for sale on his website. Impact on Travis Scott's Concert A concert on 17 July by West's fellow US rapper Travis Scott at Hellwatt festival has also been cancelled due to the two festivals being scheduled on consecutive days. Scott faced criticism after 10 people aged between nine and 27 died at his Astroworld festival in Houston, Texas, in 2021. Previous Cancellations and Apologies In April, West's show in Marseille, France, was postponed after he had been denied a UK visa earlier that month. That led to the cancellation of his headline appearances at London's Wireless festival, following backlash due to antisemitic remarks. West released a statement apologizing for his actions, stating 'I am not a Nazi or an antisemite. I love Jewish people.' Future Performances West will perform at Istanbul's Atatürk Olympic Stadium in Turkey on Saturday and is still due to perform at the GelreDome football stadium in Arnhem, the Netherlands, on 6 and 8 June.

Premier Group Recruitment entered administration in September with nearly £2.9m of debt, including £647,000 owed to HMRC. Three days later, its 99% shareholder Andrew Woosnam bought the assets through PGGBR Ltd, promising a staggered payment plan while dangling an all‑expenses‑paid staff trip to Las Vegas.Asset Buy‑Back and the Vegas IncentiveThe new entity announced a “END OF YEAR TRIP 2026” on LinkedIn, positioning the incentive as a driver for sales targets. However, administrators now report missed instalments and a shortfall in the agreed cash flow.The Money Trail: Debt, Loans and Promised PaymentsInitial cash outlay: £10,000Planned instalments: £25,000 per month for two years, totalling £600,000Outstanding director’s loan from the defunct firm: £1.2mDividends extracted since 2022: almost £2mCompeting bid rejected: £321,000 cash plus an estimated royalty of £110,000Regulatory and Taxpayer Implications of PhoenixismThe case highlights criticism of “phoenixism”, where directors shed liabilities while retaining assets. HMRC estimates that phoenix activities account for about 22% of the £3.8bn tax losses reported in 2022‑2023, raising questions about the adequacy of current safeguards.Outlook: Recovery Prospects and Potential Policy ResponseAdministrators cite a fixed charge against Woosnam’s matrimonial property and a standing order payment, suggesting eventual recovery. Nonetheless, the missed payments and the high‑profile Vegas promise may prompt tighter scrutiny of phoenix transactions and stronger creditor protections.